Newsroom

SINGAPORE--(BUSINESS WIRE)--Hafnia Limited (“Hafnia”, the “Company”, OSE ticker code: “HAFNI”, NYSE ticker code “HAFN”) will release its Q3 2026 results at approximately 07:30 CET on the 18th of November 2026. In connection with this release, Hafnia will hold an online investor presentation with Søren Steenberg Jensen (CEO), Perry van Echtelt (CFO), Søren Skibdal Winther (EVP, Commercial), and Thomas Andersen (SVP, Investor Relations, Research and Performance). The details are as follows: Date:...

TOKIO--(BUSINESS WIRE)--La Association of Japanese Animations (AJA) anunció el lunes 2 de noviembre, durante la clausura del evento principal de TOKYO ANIME NEXT —celebrado en el Tokyo Tatemono Brillia HALL, en Ikebukuro (Tokio)—, que sus nuevos premios de anime, cuyo lanzamiento está previsto para 2027, se denominarán Nippon Anime Awards. Asimismo, la AJA dio a conocer el eslogan de los galardones: “Moving Frames. Moving Hearts. Moving the World“, así como la fecha y el lugar de la ceremonia i...

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to host in-person and virtual event on IPH4502 on November 18, 2026...

MARSEILLE--(BUSINESS WIRE)--Regulatory News: Innate Pharma S.A. (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui l’organisation d’un événement dédié à IPH4502, son ADC propriétaire ciblant Nectine-4. Cet événement se tiendra à Londres, à l’IET London, Savoy Place, dans un format hybride (en présentiel et virtuel) le mercredi 18 novembre 2026 à 16h00 GMT / 17h00 CET / 11h00 ET. Le Professeur Yohann Loriot, M.D., Ph.D. (Gustave Roussy), interviendra aux cô...

ESSEN, Germany & LONDON--(BUSINESS WIRE)--RWE, one of the world’s leading renewable energy companies, and KKR, a leading global investment firm, are jointly delivering the Vanguard West and Vanguard East offshore wind projects in the British North Sea. Together, the projects represent one of the UK’s largest offshore wind developments, with a combined generation capacity of around 2.8 gigawatts. The projects represent a total investment of around £12 billion, including the construction of the w...

NEW YORK--(BUSINESS WIRE)--What do a 16-year-old baker, a world-renowned athlete, a Hollywood icon and a community changemaker have in common? The power to make the world a kinder place. In celebration of World Kindness Week, nonprofit organization kindness.org unveiled the inaugural KIND100, recognizing 100 individuals whose actions are transforming lives and communities. Bringing together global icons and everyday changemakers, KIND100 celebrates a different kind of influence, one measured by...

MADISON, Wis.--(BUSINESS WIRE)--La Administración de Alimentos y Medicamentos de los EE. UU. (FDA) ha aprobado el Promega OncoMate® MSI Dx Analysis System diseñado para identificar pacientes con tumores sólidos con alta inestabilidad de microsatélites (MSI-H) como diagnóstico complementario diseñado para KEYTRUDA®, la terapia anti-PD-1 de Merck (conocida como MSD fuera de EE. UU. y Canadá). OncoMate® MSI Dx Analysis System es un ensayo basado en PCR diseñado para evaluar el estado de MSI en tej...

MADISON, Wisconsin--(BUSINESS WIRE)--La Food and Drug Administration (FDA) américaine a approuvé le système d’analyse Promega OncoMate® MSI Dx, conçu pour identifier les patients atteints de tumeurs solides présentant un statut de microsatellites élevé (MSI-H), en tant que test diagnostique compagnon destiné à KEYTRUDA®, le traitement anti-PD-1 de Merck (connu sous le nom de MSD en dehors des États-Unis et du Canada). Le système d’analyse OncoMate® MSI Dx est un test basé sur la PCR, conçu pour...

MADISON, Wis.--(BUSINESS WIRE)--Het Amerikaanse FDA (U.S. Food & Drug Administration) heeft het Promega OncoMate® MSI Dx Analysis System, ontwikkeld om patiënten te identificeren met solide tumoren met hoge microsatellietinstabiliteit (MSI-H), goedgekeurd als companion diagnostic bedoeld voor KEYTRUDA®, de anti-PD-1-therapie van Merck (bekend als MSD buiten de V.S. en Canada). OncoMate® MSI Dx Analysis System is een op PCR gebaseerde test ontwikkeld om MSI-status in weefsel van solide tumor...

MADISON, Wisconsin--(BUSINESS WIRE)--La Food and Drug Administration (FDA) degli Stati Uniti ha approvato il sistema di analisi Promega OncoMate® MSI Dx, progettato per identificare i pazienti affetti da tumori solidi a elevata instabilità dei microsatelliti (MSI-H), come soluzione diagnostica complementare per KEYTRUDA® , la terapia Merck anti-PD-1 (nota come MSD al di fuori degli Stati Uniti e del Canada). Il sistema di analisi OncoMate® MSI Dx è un saggio basato sulla PCR concepito per valut...